Fig. 1.

a Endometrial cancer-related survival by 4 molecular subgroups in the PORTEC-2 trial for high-intermediate risk EC. b Total pelvic recurrence by unfavorable risk factors (LVSI, p53-mutant, or L1CAM expression). Reproduced from Wortman, B.G., et al., Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer, 2018. 119(9): p. 1067-1074, which is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), courtesy of the authors